Kau S T, Halterman T J, Yochim C L, Howe B B, Li J H, Schwartz J A
Department of Pharmacology, ZENECA Pharmaceuticals Group ZENECA Inc., Wilmington, DE 19897.
Pharmacology. 1994 Mar;48(3):167-75. doi: 10.1159/000139176.
ZENECA ZM224,832 is a novel eukalemic diuretic from the aminomethylphenol pyrazine series which demonstrated a profile of calcium channel blockers. It produced diuretic and saluretic effects in animals but had only minimal alterations in kaliuresis after oral administration. In contrast to standard diuretics, the plasma K+ concentration was not altered in conscious dogs treated for 14 days with ZENECA ZM224,832 and the concurrent plasma renin activity was also minimally elevated. The isolated rat aorta evaluation indicated that ZENECA ZM224,832, like tiapamil and nifedipine, inhibited vascular smooth muscle tone by inhibiting voltage-dependent calcium channels. ZENECA ZM224,832 produced a dose-dependent decrease of blood pressure in spontaneously hypertensive rats (SHR) in which the antihypertensive activity was not noted with HCTZ. In addition, ZENECA ZM224,832, similar to diltiazem, produced an acute blood pressure lowering effect in nephrectomized SHR which was independent of its diuretic activity. It is concluded that ZENECA ZM224,832 is a potent eukalemic diuretic with calcium channel blocking properties.
捷利康ZM224832是一种新型的氨基甲基苯酚吡嗪类真性血钾正常利尿剂,具有钙通道阻滞剂的特性。它在动物身上产生利尿和促尿钠排泄作用,但口服给药后对尿钾排泄的影响极小。与标准利尿剂不同,用捷利康ZM224832治疗14天的清醒犬血浆钾浓度未改变,同时血浆肾素活性也仅有轻微升高。离体大鼠主动脉评估表明,捷利康ZM224832与替帕米和硝苯地平一样,通过抑制电压依赖性钙通道来抑制血管平滑肌张力。捷利康ZM224832能使自发性高血压大鼠(SHR)血压呈剂量依赖性下降,而氢氯噻嗪对其无降压活性。此外,捷利康ZM224832与地尔硫卓相似,在肾切除的SHR中产生急性降压作用,且该作用与其利尿活性无关。结论是,捷利康ZM224832是一种具有钙通道阻滞特性的强效真性血钾正常利尿剂。